Wholesale Marketplace Faire Launches in the UK to Power the Growth of Independent Retailers
Faire, the online wholesale marketplace valued at $2.5 billion (£1.9 billion), today announced its expansion into Europe, bringing its global network of curated brands and powerful business tools to independent retailers across the United Kingdom. The platform will launch in the United Kingdom and Netherlands, with other European markets to follow in the coming months, accelerating Faire’s mission of empowering entrepreneurs everywhere.
Since its founding in 2017, Faire has been dedicated to transforming retail by providing the tools and technology small businesses need to thrive and compete with major retail chains, despite historical operational disadvantages. Growing 200% year over year, Faire currently serves over 170,000 independent retailers across North America, representing more retail locations than Marks & Spencer, Boots, Aldi, Starbucks, and Tesco combined. Additionally, Faire’s brand community has grown to over 15,000 brands based in over 70 countries, with the United Kingdom representing the third largest demographic of brands on the platform.
“We believe that with the right technology and resources, the independent retail community is an unstoppable force even in the face of insurmountable odds,” said Faire CEO, Max Rhodes. “We are thrilled to begin servicing retailers in the UK, and also recognise that the challenges facing the retail landscape in Europe are unique. That’s why we’re grateful to be partnering with both global and local organizations including the Department for International Trade and London & Partners to ensure we can provide the distinctive support needed to tackle the demands facing the international retail industry today.”
Faire provides a holistic, end-to-end platform that enables independent retailers to build, grow, and run their businesses. As the UK plans for the reopening of non-essential retail later this spring, Faire will be an essential partner for retailers looking to prepare and restock, providing a simple but powerful toolkit of data insights, payment terms, and logistical solutions. Independent retailers across the United Kingdom that leverage the Faire platform will benefit from:
● Access to a global network: With over 15,000 international brands, Faire enables retailers to discover unique products from around the world, including high-quality items not sold on Amazon, a competitive strength against the mainstream goods found on High Street.
● Competitive credit terms: Faire offers net-60 terms to purchasing retailers, providing more payment flexibility and security, a benefit that was previously only available to big-box stores.
● Free returns: Faire is the first wholesale marketplace to offer free returns on opening brand orders, eliminating the burden of inventory risk by allowing retailers to experiment and buy with confidence in an unpredictable environment.
● Shipping solutions: Faire provides industry-leading solutions that help small businesses adapt to a post-Brexit market by supporting country-specific pricing and product-level tariff codes, as well as competitive international shipping rates through Ship with Faire. Additionally, for a limited time, Faire will be funding free shipping to European retailers.
● Data-backed insights: Through machine learning, Faire’s algorithm offers smart, data-driven recommendations and insights on what will likely sell well for a specific retailer.
As part of Faire’s international expansion, the company will establish operations in London by opening an office with plans to hire dozens of employees. The move into London will build on Faire’s partnership with the Department of International Trade, in an effort to accelerate the growth of UK based brands across the globe. “Faire’s decision to open their first European office in London shows a true vote of confidence in the UK consumer and retail sectors as we Build Back Better from Covid-19,” said Department for International Trade Minister for Investment, Gerry Grimstone. “This expansion is great news for small businesses up and down the country looking to enter international markets and diversify their sales channels. I look forward to our continued partnership with Faire and wish them every success as they scale up and grow.”
Looking ahead, over 60% of consumers in the United Kingdom have reported believing shopping from small businesses offers something unique,1 while American Express2 data revealed that 40% of consumers have increased their spend at local businesses in the past year. This, coupled with the Bank of England3 predicting a spending boom as a result of household savings totalling £250 billion over the past year, illustrates a promising outlook for the reopening of independent retailers across the region.
Faire’s expansion into Europe marks a step towards creating a truly globalised marketplace where local retailers and brands around the world can seamlessly connect and meaningfully compete against retail giants.
About Faire:
Faire is a wholesale marketplace taking a data-driven approach to connect local, independent retailers with the best brands and artisans to stock their shelves with the best goods. Faire retailers rely on Faire for the convenience of ordering from thousands of their favourite brands all in one place, net 60 payment terms, free returns on opening orders, and freight caps. For brands, the platform provides powerful sales, marketing, and analytics tools, so sellers can simplify their wholesale business and focus on making great products.
Company highlights:
● Founded in 2017 by Square (NYSE: SQ) alumni Max Rhodes (CEO), Marcelo Cortes (CTO), Jeff Kolovson (COO), and Daniele Perito (CDO). Headquartered in the United States and Canada.
● Faire is valued at $2.5 billion (£1.9 billion), with $439 million (£315 million) total funding raised to date from global investors including Y Combinator, Lightspeed Venture Partners, Sequoia Capital, Forerunner Ventures, Khosla Ventures, Founders Fund and Norwest Venture Partners.
● Faire has more than 400 employees with offices across the United States and Canada. Faire is actively hiring in the UK and plans to open an office in London.
● The platform supports over 185,000 brands and retailers. To date, 13,000 retailers based in North America have stocked their shops with Europe based brands.
1 Enterprise Nation, November 2020
2 American Express, November 2020
3 Bank of England, February 2021
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210323005078/en/
Contact information
Tara Harandi-Zadeh
07808544490
Tharandi-zadeh@thisisoutcast.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
